Drastically elevated levels of Interleukin-6 and its soluble receptor complex in COVID-19 patients with acute respiratory distress

Gaetano Di Spigna, Daniela Spalletti Cernia, Maria Vargas, Luigi Buonavolontà, Giuseppe Servillo, Loredana Postiglione

Clinical and Medical Investigations · 2020 · 16 citations · 5 references

DOIFull text

Open access

Concepts

Abstract

In December 2019 a novel RNA beta-corona virus, highly contagious, was recognized to be the cause of previously pneumonia cases of unknown origin.The virus is phylo-genetically similar to SARS-CoV and has been called SARS-CoV-2 (COVID-19).Most common is the emerging of a strong dys-regulation of the immune response, that leads to disease severity in COVID-19 patients.There are a lot of suggestions indicating that mortality, strong in critically ill patients, might be correlated with virally driven hyper-inflammation, due to a cytokine storm.Interleukin-6 (IL-6) plays an important role in cytokine release syndrome and elevated IL-6 level is a hallmark inflammatory signature seen in serum of patients with severe COVID-19 acute respiratory distress (ARDS).We analyzed blood inflammation indicators, IL-6 and its receptor complex and TNF-α, in order to demonstrate that cytokines unbalanced systems can be considered an early tool to identify critical patients and to predict their poor prognosis.Our study was conducted on N=23 critically patients with confirmed COVID-19 and admitted in Intensive Care Unit (ICU) from March 10 to April 30 due to severe respiratory failure.Serum levels of IL-6, sIL-6R, sgp130 and TNF-α were determined using CLIA and ELISA as immunoassay.Our data shown that not all patients have higher values in serum of sIL-6R agonist receptor, compared to the controls.For this reason we have stratified all patients in two different group (1 and 2).We observed that in GROUP 1 as well as in GROUP 2 the IL-6 and TNF-α serum levels are significantly increased in respect to the controls.Despite, sgp130 antagonist receptor levels are significantly decreased in all patients.Further studies are required to better investigate the role of IL-6 and its soluble receptor complex during COVID-19 disease and to evaluate the possible involvement of other cytokines also in response to different pharmacological treatment.

References

5